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Injecting drug use is a public health problem in need of novel 
intervention. Heroin and cocaine, two commonly injected drugs, 
highly contribute to overdose death. Overdose is now the number 
one cause of unintentional death in the United States. Those who 
inject drugs are also at risk of infectious diseases such as HIV and 
HCV. Current methods to reduce the harms associated with in-
jecting drug use are not meeting the needs of injecting drug users 
(IDUs). In many parts of the world, injecting drug use is tolerated 
and permitted at supervised facilities where medical staff are avail-
able as needed. 
To determine if such facilities are possible in the United States 
this literature review of research related to safe injecting facili-
ties (SIF) was conducted. The databases PsychInfo and CINAHL 
Complete were utilized in this review. Thirty-two articles were 
considered, and five were excluded. Twenty-seven comprised the 
final literature review. It is clear that SIF will be utilized by IDUs. 
These facilities will serve to reduce risk of overdose, reduce disease 
transmission, increase treatment access, and provide a valuable 
service to the neighboring community. Further research and 
education are needed to gain public support for these lifesaving 
community interventions in the United States.
Introduction 
Injection drug use is a public health problem that has been dif-
ficult to address, because of negative views on individuals who 
inject and limited treatment options. Individuals injecting drugs 
face high risk of contracting infectious diseases and premature 
death from overdose. The drug users are often forced to inject in 
unsanitary public settings, placing not only them at risk, but the 
general public (Green et al., 2003; Navarro & Leonard, 2004). 
Present interventions include arrest and dispersing injecting 
drug users (IDUs), forcing them away from proactive treatment 
services, further into the challenges and risks of injecting drug use. 
It has been shown that for every dollar spent on treatment, sevens 
dollars are returned (Ettner et al., 2006). In order to experience 
these results, novel interventions allowing IDUs to access medical 
services must be made available.
Rates of overdose death related to drug use have been steadily 
climbing since 1970 (CDC, 2010). In 2008, cocaine was involved 
in almost 500,000 emergency department visits for overdose and 
heroin was involved in over 200,000 (CDC, 2010). Between 1999 
and 2004, the rates of overdose deaths almost doubled from over 
12,000 to over 20,000 (Paulozzi & Annest, 2007) and have now 
surpassed car accidents as the leading cause of accidental death 
in the United States, taking the lives of nearly 40,000 annually 
(CDC, 2013). 
Nationally, injecting drug use is the third leading cause of HIV 
infection (Grigoryan et al., 2009). According to the Centers for 
Disease Control and Prevention (CDC), from 2004-2007, almost 
20,000 new cases of HIV were identified in IDUs (Grigoryan et al., 
2009). Those between the ages of 35-44 were the most likely age 
group diagnosed. The majority of these individuals (74%) lived 
in urban areas. Black or African American males were the mostly 
likely diagnosed, accounting for over 17% of new cases. Hepatitis 
C (HCV) is another common infection transmitted by injection 
drug use, affecting almost 45% of the IDUs between the ages of 
18-29 (Koh & Valdiserri, 2013). IDUs face challenges obtaining 
sterile syringes, a key resource to engage in safe injecting practices 
to limit disease transmission (Heller, Paone, Siegler, & Karpati, 
2008). 
Connection to treatment services is vital to reducing over-
dose deaths and preventing disease transmission. Yet few will-
ingly engage in treatment unless they consider their use to be a 
problem. They may also decide that the benefits of use - e.g., for 
dealing with trauma, grief or pain - outweigh the costs. Use can 
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also promote a sense of belonging and allow individuals to have 
positive experiences. Some are embarrassed to seek treatment 
due to stigma, and many are unprepared to follow the objectives 
of a traditional treatment program (Prochaska, DiClemente, & 
Norcross, 1992; Witkiewitz, 2005). Individuals frequently express 
a desire to seek treatment (Prochaska et al., 1992). However, most 
are only able to access programs that view substance use or users as 
immoral or diseased (Marlatt & Witkiewitz, 2002). By not adher-
ing to an abstinence-only model, individuals are often blocked 
from treatment, labeled as noncompliant, and identified as abusers 
of the system. Help, according to the current model, is only avail-
able for those with the desire to abstain and who have hit their 
bottom (Mac Master, 2004). In practicing this type of exclusion, 
treatment programs are ignoring basic health and societal risks 
associated with injection drug use. Access to healthcare resources 
must be made available to the most marginalized populations of 
drug users.
In many parts of the world, injecting drug use is being tolerated 
at specific programs termed safe injecting facilities (SIF) or safe 
consumptions facilities (SCF). For the purpose of this review, 
the focus will be on SIF because they are directed specifically 
at injecting drug users and provide a range of healthcare and 
ancillary services. SCF are more commonly associated with toler-
ant places to both smoke and inject drugs, often with minimal 
intervention (Wolf Linssen, & de Graff, 2003). As of 2003, there 
were 50 formal SIF in six countries, one of which is located in 
North America (Broadhead et al., 2003). These facilities differ to 
varying degrees on how they provide assistance to injecting drug 
users (Wolf et al., 2003). Historically, these programs faced many 
challenges initiating their services due to a lack of evidence sup-
porting their implementation (Wodak, Symonds, & Richmond, 
2003). In Australia, underground injecting rooms snowballed into 
public requests for a scientifically evaluated SIF (Wodak, et al., 
2003). The present literature review aims at examining available 
literature about SIF to develop a clear picture of the benefits and 
challenges of opening a SIF in the United States and also identify 
areas for further research.
Search Strategy 
Peer-reviewed journal articles were searched utilizing the data-
bases PsychInfo and CINAHL Complete. Articles were obtained 
between 1980 and 2013 to include the years when harm reduc-
tion strategies began gaining momentum and include up-to-date 
publications. To examine publications specific to opinions of safe 
injection facilities (SIF) and the potential impact of SIF on inject-
ing drug users (IDUs) and the community, criteria included ar-
ticles which were peer reviewed, were samples of adults (age 18+), 
and published in English. Search terms included combinations of 
searches for safe/safer/supervised injecting/injection facility/facili-
ties and qualifiers of opinion, public, perceptions, consideration, 
and perspective. These searches yielded between 2 and 19 results. 
To examine reasons for safe injection facilities, a search was con-
ducted for safer injection and illicit drugs. This strategy returned 
17 results. 
 Titles and abstracts were examined to determine if SIF were men-
tioned. A total of 32 articles which mentioned SIF were cataloged 
and each complete article was read to determine if the authors ad-
dressed opinions, benefits, or use of SIF. Five articles were excluded 
in the final literature review. One article was not included because 
it did not scientifically explore opinion, but provided a narrative 
of the progression from underground operation to legal entity 
in Australia (Wodak, Symonds, & Richmond, 2003). Another 
described facilities in the Netherlands through a literature review, 
observation, and interview process (Wolf et al., 2003). Three 
other excluded articles explored syringe access and use within the 
community (Heller, Paone, Siegler, & Karpati, 2009), provided 
demographic description of public injectors and factors related to 
public injection (Navarro & Leonard, 2004), and described pat-
terns of injecting drug use as a basis for opening a facility (Green 
et al., 2003). Excluded articles were included in the introduction 
to this review. The remaining 27 articles comprise the present 
literature review. The articles were grouped to explore opinions of 
use and implementation of SIF, utilization of SIF, benefits of SIF, 
and considerations for further implementation and improvement 
of SIF. 
Literature Review 
Articles included in this review stemmed from pre- and post-
implementation of North America’s first SIF, Insite, in Vancouver, 
Canada. Despite the search criteria range of 1980-2013 the major-
ity of articles were from the years 2003 and 2007. These years 
include the year prior to implementation and four years into as-
sessment of Insite, respectively. Articles also addressed the nature 
of SIF in Australia and considerations of current injecting drug 
users in San Francisco and New York City. Readers will note that 
in North America, these three cities are also home to organized 
and public groups termed Drug Users Unions, which advocate for 
resources and interventions to reduce negative outcomes for cur-
rent and former drug users. The following review is arranged into 
categories associated with opinions of opening and utilizing SIF, 
benefits and challenges of SIF, and additional considerations. 
Of the 27 articles included in this review, 10 utilized data from 
the Scientific Evaluation of Supervised Injecting (SEOSI) cohort 
or interviews with participants. This is a formal evaluation of 
Vancouver’s SIF. Random recruitment for the SEOSI took place 
at Insite. A computer alerted staff to recruit participants randomly 
on their second visit to the SIF. An interviewer-administered ques-
tionnaire was conducted. Blood samples to test for HIV and HCV 
were also taken. A total of 1065 participants were included over a 
two year period from 2003 to 2005.
Studies addressing implementation, desire to use and actual 
usage of SIF 
Thirteen articles addressed the consideration of IDUs to utilize a 
SIF, potential considerations by the general community and key 
informants, or investigated the use of available SIF. These studies 
included qualitative interviews with current IDUs and reviews of 
registrations at the facilities. Risk factors leading to utilization, 
reasons for or against attending, and possible challenges were ad-
dressed. 
Four articles surveyed current IDUs to determine if they would be 
willing to attend a SIF with estimates of considered use ranging 
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from 38% to 92% of IDUs. These studies took place in Vancouver, 
Canada (Kerr et al., 2003, Kerr, Wood, Small, & Palepo, 2003), 
New York City, New York (Broadhead et al., 2003), and San 
Francisco, California (Kral et al., 2010). The studies conducted 
by Kerr and colleagues identified that up to 92% of IDU would 
be willing to utilize a SIF (Kerr et al., 2003). These numbers were 
largely lower in cocaine-using populations where 38% reporting 
willingness and 62% said they would not use a SIF (Kerr, 2003). 
In New York City, 80% of current needle exchange participants 
were willing to utilize a SIF and this increased to 93% for those 
who regularly injected in public places (Broadhead et al., 2003). 
Finally, Kral et al. (2010) identified that 85% of IDU in San Fran-
cisco would be willing to attend a SIF. 
Those who were more likely to use a SIF were also higher risk 
injectors, placing them at more risk for HIV and HCV (Broadhead 
et al., 2003; Wood et al., 2005). These individuals were more 
likely homeless, more likely to share needles and other injec-
tion equipment, and frequently injected with strangers (Anoro, 
Ilundain, & Santisteban, 2003; Broadhead et al., 2003; Wood et 
al., 2005). Participants also reported they were more likely to have 
difficulty obtaining clean syringes, require help injecting, report 
frequent heroin injecting, inject in public places, (Broadhead et 
al., 2003; Wood et al., 2005; Kerr, Small, Moore, & Wood, 2007) 
and be involved in the sex trade (Kerr et al., 2007). Individuals 
who would consider using a SIF frequently reported that they 
thought the facility would help improve their safety, not only 
from risk directly associated with injecting, but also from assaults, 
robbery, murder, and arrest (Kerr et al., 2003; Jozaghi & Andresen, 
2013). It is important to note only those who reported injecting in 
the past six months were included in the studies. Only one study, 
Wood et al. (2005), identified that this could be a possible limita-
tion, skewing results toward the higher risk individuals. 
One study investigated the opinions of key stakeholders. This 
study took place in Tijuana, Mexico and included 40 key stake-
holders from various sectors including religious groups, politicians, 
and medical personnel (Philbin et al., 2008). The authors’ goals 
were to investigate the feasibility and acceptance of three harm 
reduction strategies, needle exchange, syringe vending machines, 
and SIF. The authors found that SIF were the least acceptable and 
least possible of the harm reduction strategies, with 58% consider-
ing SIF acceptable, but only 25% acknowledging that SIF were a 
possible intervention (Philbin et al., 2008). Those in the religious 
sectors were most opposed, considering SIF insufficient and likely 
to promote drug use. Philbin et al. (2008) received no consents for 
interviews from those in law enforcement. 
These results were similar to a general community survey in 
Ontario, Cananda in which 60% agreed SIF should accessible for 
IDUs (Cruz, Patra, Fischer, Rehm, & Kalousek, 2007). Support 
for SIF in Australia was much higher than North America. In 
telephone interviews conducted prior to and following the imple-
mentation of Australia’s first SIF, both residents and businesses 
reported nearly 80% support of SIF access (Thein, Kimber, Maher, 
MacDonald, & Kaldor, 2005). These interviews also identified 
that the community did not think SIF would increase the rate of 
injecting (Thein et al., 2005). 
Four studies identified the use of current SIF through registrations 
and interviews. First, van Beek (2003) found that 4,719 individu-
als were registered in the first two years of Australia’s Medically 
Supervised Injecting Centre (MSIC). In this time period over 
88,000 injections took place at an average of 226 per day (van 
Beek, 2003). In Barcelona 1,677 people registered in the first 
year of EVA (Anoro et al., 2003). By 2006, 6,747 individuals had 
registered at Vancouver’s Insite (DeBeck et al., 2011). 
It was found that the majority of users utilized the SIF infre-
quently, with 57% reporting less than 25% of injections took place 
at the SIF, 25% used a SIF for 26% to 74% of injections, and 7% 
reported use for all injections (Wood et al., 2005). On weekends 
the SIF saw an increase in participants from areas outside the 
immediate neighborhood (Anoro et al., 2003). In only one report 
was a person’s first injection completed at a SIF, despite the fact 
that over 100 individuals annually initiate injection each year in 
the area (Kerr et al., 2007).
Studies addressing overdose
Six journal articles included in this review addressed overdose. 
These articles highlight that SIF are saving lives (Kerr et al., 2007; 
Jozaghi & Andersen 2013). In cities surveyed without access to a 
SIF, overdose is regularly associated with death (Jozaghi & Ander-
sen, 2013). IDUs present when someone overdoses often do not 
know what to do (Jozaghi & Andersen, 2013) and may abandon or 
steal from the individual overdosing (Kerr et al., 2007). By history, 
over 58% of the SEOSI cohort reported past non-fatal overdoses 
(Milloy et al., 2008). Since utilizing the SIF, less than 10% re-
ported experiencing non-fatal overdoses (Milloy et al., 2008). 
The reduction in non-fatal overdoses is important as it refutes op-
position claims that SIF would increase the likelihood of overdoses 
(Milloy et al., 2008). Marshall, Milloy, Wood, Montaner, and Kerr 
(2011) examined coroner reports for accidental overdose in the 
city of Vancouver between 2001 and 2005. There were a total of 
290, but the authors found a 35% reduction in the area surround-
ing the SIF and a 9% reduction in other areas after it opened. It 
should be noted that there was also a 15-day spike in overdose 
deaths after the SIF opened due to powdered methadone being 
added to heroin (Marshall et al., 2011). SIF participants report 
one important factor preventing overdose – their ability to take 
their time and sample drugs for purity and strength (Kerr et al., 
2007). 
SIF are able to prevent overdose deaths because of the rapid 
response by staff (Kerr et al., 2007) and the availability of life sav-
ing equipment and the medication Narcan (naloxone), an opioid 
antagonist that binds to opioid receptors flushing out and prevent-
ing further intake of opioids (Anaro et al., 2003; Kerr et al., 2003). 
Over a two-year period, there were 553 overdoses managed at 
MSIC in Australia (van Beek, 2003) and 377 at EVA in Spain, of 
which 52% involved respiratory arrest (Anoro et al., 2003). Most 
importantly, there were no overdose deaths at the facilities in this 
time period (Anoro et al., 2003; van Beek, 2003). One statement 
from the qualitative interview by Kerr et al. (2007) sums up the 
benefits of overdose protection at a SIF – “Dead people are found 
in their room. They are not found at Insite (Vancouver’s SIF).” 
(pg 40).
Studies addressing safe injection practices
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Eight articles explored concepts of safer injection among SIF par-
ticipants. Kerr et al. (2007b) gathered data from the SEOSI cohort 
to identify the length of time individuals were injecting and the 
circumstances surrounding their first injections. Kerr et al. (2007) 
found that the majority of SIF participants were long-time IDUs 
and their median length of injecting was 15.9 years. Fast, Small, 
Wood, and Kerr (2008) conducted qualitative interviews with 50 
SEOSI participants and found that a significant lack of knowledge 
existed about safe injection practices. This was common not only 
among new injectors, but also with IDUs with over 20 years of 
experience. As noted earlier, only one person reported their first 
injection took place at the SIF (Kerr et al., 2007). From the others 
surveyed, 20% reported that their first injection was with a used 
syringe and 75% reported that it was administered by someone else 
(Kerr et al., 2007). 
At the SIF, participants could improve their safe injecting 
practices with increased access to sterile syringes and equipment 
(Anoro et al., 2003; Salmon et al., 2009; Small, Moore, Shoveller, 
Wood, & Kerr, 2012; Jozaghi & Andersen, 2013). An environ-
ment to improve injection practices was made available, exceeding 
the work of needle exchange programs and community outreach 
which often have intermittent points of contact (Fast et al., 2008). 
SIF are enhanced by staff nurses who reinforce safer practices over 
extended periods (Jozaghi & Andresen, 2013; Fast et al., 2008). 
Over 50% of participants report receiving direct support from 
nurses (Wood et al., 2008) who they viewed as experts who can be 
trusted to provide individually tailored educational messages (Kerr 
et al., 2007; Fast, 2008). 
The efforts of nurses to educate SIF participants can be seen in the 
vast improvements among participants. Salmon et al. (2009) sur-
veyed MISC participants in Australia to determine lifetime preva-
lence of injection-related problems, injuries, and diseases. Salmon 
et al. (2009) found that one third of MISC participants reported 
problems compared to 69% of needle exchange participants in the 
same area. Petrar et al. (2007) utilize the SEOSI cohort to exam-
ine perceptions of SIF impact on their injecting behavior in the 
community, finding 54% used clean water, 37% reused equipment 
less often, and 49% cleaned the injection site. Participants also 
reported less sharing of equipment (Fast et al., 2008; Jozaghi & 
Andersen, 2013). SIF participants became “safety and educational 
ambassadors” (Jozaghi & Anderson, 2013, pg 7), providing clean 
needles and encouraging the use of clean equipment and other 
practices to other IDUs in the community.
Studies investigating improvements in the community
Five studies identified the benefits to both the IDU and the non-
IDU communities surrounding the SIF. The reduced risk of police 
involvement and arrest (Small, et al., 2012; Jozaghi & Andresen, 
2013) decreased the need to rush use, a common factor in over-
dose (Kerr et al., 2007; Small, et al., 2012). Participants reported 
feeling safer at the SIF than they do on the streets. Participants at-
tributed this to reduced risk of theft, assault, and death (Small, et 
al., 2012; Jozaghi & Andersen, 2013) often attributed to overdose 
(Kerr et al., 2007). Feelings of safety at SIF were enhanced for 
women who are at increased risk of violence or exploitation when 
seeking to inject in public (Fairbairn, Small, Shannon, Wood, & 
Kerr, 2008). Participants also reported less public use and reduced 
public disposal of syringes (Jozaghi & Andersen, 2013; Petrar et 
al., 2007), reducing risk associated with HIV and HCV transmis-
sion. SIF provided environments to intervene in the case of a 
medical emergency, such as an overdose. This reduced the use 
of emergency medical services such as ambulance transport and 
emergency departments (Jozaghi & Andersen, 2013) freeing these 
services for community needs.
Studies addressing how SIF connect IDU to other services 
Seven studies examined the potential enhancement of service 
utilization by SIF participants. In an evaluation of the SEOSI co-
hort and factors associated with injection cessation, Debeck et al. 
(2011) identified that in tolerating use of illicit drugs, SIF provide 
a space for a hidden population to enter a healthcare setting on 
their terms, positively impacting connections to services. SIF par-
ticipants report the ability to connect with counselors and nurses 
for a variety of services. Jozaghi & Andresent (2013) contrasted 
this report with IDU in cities surrounding Vancouver without ac-
cess to a SIF. These individuals were not interested in looking for 
service because their healthcare focus was finding a clean needle. 
However, regular use of a SIF and contact with counselors was 
positively associated with entering drug and alcohol treatment 
programs (Debeck et al., 2011). 
Staff were seen as facilitators of treatment and ancillary services 
because they were caring and allowed for trust to be built (Fast, 
2008; Small, Wood, Lloyd-Smith, Tyndall, Kerr, 2008; Jozaghi & 
Andresen, 2013). There were about 1,800 referrals to health and 
social services in the first two years of MISC in Australia, 44% 
of which were to drug and alcohol treatment (van Beek, 2003). 
Additionally, 23% of the SEOSI cohort reported they stopped 
injecting for a period of at least six months (DeBeck et al., 2011). 
Frequently, participants held stable jobs (Anoro, 2003) with over 
36% reporting having a regular job in the past six months (Rich-
ardson et al., 2008). It must be noted that regular use of the SIF 
was not associated with employment. Only binge use was associ-
ated with employment, highlighting that some may concentrate 
their use in order to maintain work (Richardson, 2008).
Further considerations
Nine studies address topics related to the previous sections and 
supplement the findings. First, Andresen and Jozaghi (2012) and 
Jozaghi, Reid, and Andresen (2013) examined the cost-benefit 
analysis of SIF in Canada through a mathematical model. If SIF 
were to be opened in Montreal, there could be 14-53 fewer HIV 
cases and 84-327 fewer HCV cases, resulting in about $1.5 mil-
lion in savings annually. These savings do not account for other 
healthcare costs, such as overdose and infections at the injection 
site (Jozaghi et al., 2013). The authors note that in order to ex-
pand the cost savings of a SIF, it must attract new IDUs and thus 
open in new areas accessible to IDUs and not served by a present 
SIF (Andresen and Jozaghi, 2012). 
Significant factors must be considered which may impede use of 
SIF. Operational procedures in particular may turn IDUs away; 
particularly wait times, monitoring, need to present ID and regis-
ter, and police presence (Kerr et al., 2003; Kerr et al., 2007; Petrar 
et al., 2007; Kral et al., 2010). Hours of operation also need to be 
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considered (Petrar et al., 2007), rules on sharing drugs, limits on 
numbers of injections, and the specific needs of cocaine toxicity 
may also discourage participation by IDU (Kerr et al., 2003). 
Conclusion 
It is clear that a large portion of IDUs are willing to utilize SIF. 
These individuals are often at higher risk and will benefit from the 
support and clean environment of a SIF. There are overwhelming 
numbers of individuals actively using SIF in six countries. The 
evidence is clear from this utilization, if opened SIF will save lives 
and improve health. In many cases, the availability of SIF can be 
the best protection from overdose by allowing IDUs to take their 
time and be in the presence of trained staff with resources to inter-
vene and prevent deaths that would normally occur in the streets 
or homes of IDUs. 
The improvement in safer injection practices was seen not only at 
the SIF, but also within the surrounding communities. Those who 
use SIF helped spread messages of safety within the injecting drug 
using community not engaged with the SIF. The process of moving 
injection drug use off the streets and out of alleys places less risk 
on IDUs in regard to their safety, arrest, and disease transmission. 
IDUs were not the only ones to benefit, the general public who 
share these same communities witnesses cleaner, safer neighbor-
hoods as well. Emergency services which had frequently been 
burdened by IDUs were now available for others. The emergency 
services needed could be administered at the SIF. 
Connections to services outside the SIF are key evidence to the 
benefit of SIF as well. It is clear reaching more at risk populations 
enables SIF staff to provide access to services that would otherwise 
be avoided. The trust of staff and the educational opportunities 
provided can help to facilitate those connections. This trust was 
built over time, by visiting with the same health professionals who 
were nonjudgmental and caring. IDUs were provided with hope, 
a tool often withheld from them on the street and in traditional 
treatment settings. When an individual was ready for traditional 
treatment they had the access to the same caring professionals 
who could facilitate the connection. 
The present literature review examines aspects of available 
research about SIF. The results of this research may be limited by 
the search criteria. The majority of SIF and SCF available are in 
non-English speaking countries, but this author could only utilize 
journal articles published in English. Translation of non-English 
reviews should be considered for further research. Additionally, 
two articles were found which gauged the general public’s opinion 
about SIF, one in North America. Only two studies identified in 
this review took place in the United States. SIF are a relatively 
new intervention and therefore little research is available. Un-
derstanding public opinion is necessary to implementing a SIF, as 
the community can petition for or against such facilities in their 
neighborhoods.
If SIF are to be considered, further research is needed in the best 
methods for gaining community support, addressing political 
challenges, and identifying the optimal design of such facilities. 
Key stakeholders should be included in these discussions. These 
individuals should include current drug users, former drugs users, 
their families, community members, policy makers, drug treatment 
professionals, medical professionals, law enforcement, and public 
health professionals. Evidence of the benefits of SIF are growing, 
but previous attempts to implement SIF demonstrate that imple-
mentation will be challenging. As stated in the literature review, 
key stakeholders may find SIF acceptable, but do not foresee 
their implementation likely. It will take strong connections with 
community leaders, research, education, and positive advocacy to 
implement a SIF and save the lives of many in need. 
The problem with our current system is that “Dead addicts don’t 
recover” (Mac Master, 2004, p 358) but traditional approaches 
wait for them while community level intervention push IDUs fur-
ther from help. SIF provide access to life-saving interventions and 
quality healthcare which may give IDUs the chance to recover. 
We must remember that not everyone is prepared or capable of 
ending their use. Instead many pathways need to be available. SIF 
will reduce disease transmission and remove overdose as the lead-
ing cause of accidental death. If we can improve the quality of life 
for IDUs we may also improve the health and wellbeing of many 
others in the United States.
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